Episode 61: Is Sotatercept safe in patients with PAH?
Description
On this episode of JHLT: The Podcast, the Digital Media Editors invite author Ioana Preston, MD, to discuss the paper, “Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLAR.”
Dr. Preston is the director of the pulmonary hypertension center at Lahey Hospital and Medical Center in Burlington, Massachusetts, and has over 20 years of experience in caring for patients with PH, as well as multiple clinical trials in PH.
The episode explores:
- What makes sotatercept unique as the first “biologic” in the treatment of PAH
- Hypotheses about the mechanism of action in sotatercept
- Sotatercept’s interaction with mPAP and what it indicates about the drug’s action on the pulmonary vasculature
For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you’re an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.
Those involved in the heart failure and mechanical circulatory support should tune in again later this month for a study on apixaban plasma levels in patients with HeartMate 3 support.
Don’t already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.
United States
